Skip to main content

Table 2 Characteristics of the included studies

From: Comparative efficacy of eight oral Chinese patent medicines for dilated cardiomyopathy with heart failure: a Bayesian network meta-analysis

Study ID

N (E/C)

Male/female

Age (years)

NYHA (I, II, III, IV)

Intervention

Duration (week)

Outcomes

E

C

E

C

E

C

E

C

Zhao et al. 2009 [18]

34/34

23/11

21/13

–

0, 14, 20, 0

0, 15, 19, 0

QLQX + CAM

CAM

4

â‘ 

Liu et al. 2009 [19]

21/20

13/8

12/8

41 ± 11

40 ± 10

0, 12, 9, 0

0, 12, 8, 0

QLQX + CAM

CAM

24

①②③④⑤

Zhu et al. 2010 [20]

40/40

–

52.3 ± 14.2

0, 20, 29, 31

QLQX + CAM

CAM

12

â‘¡â‘¢

Lin, 2010 [21]

30/30

15/15

12/18

40 ± 13

38 ± 12

–

QLQX + CAM

CAM

24

①②③④⑤

Yuan, 2012 [22]

30/32

20/10

16/16

41.65 ± 9.33

43.08 ± 7.5

0, 0, 12, 18

0, 0, 16, 16

QLQX + CAM

CAM

4

②③④

Zhao et al. 2012 [23]

34/34

21/13

23/11

–

0, 14, 20, 0

0, 15, 19, 0

QLQX + CAM

CAM

4

②④⑤

Yang et al. 2013 [24]

34/34

21/13

19/15

53.8 ± 10.1

54.6 ± 10.8

–

QLQX + CAM

CAM

12

②③⑥

Yu, 2013 [25]

32/32

19/13

20/12

59 ± 12

61 ± 12

–

QLQX + CAM

CAM

4

②③④⑤

Zhang et al. 2013 [26]

35/35

42/28

–

0, 0, 60, 10

QLQX + CAM

CAM

8

①②③⑤

Yi et al. 2014 [27]

45/45

25/20

26/19

52.4 ± 12.7

53.1 ± 13.4

0, 16, 18, 11

0, 14, 19, 12

QLQX + CAM

CAM

4

②③⑤

Wu et al. 2014 [28]

24/24

18/6

17/7

52.6 ± 10.7

53.9 ± 9.3

0, 9, 15, 0

0, 8, 16, 0

QLQX + CAM

CAM

12

â‘¡â‘£

Zhou et al. 2015 [29]

20/24

13/7

12/12

46.45 ± 28.29

47.38 ± 25.46

0, 11, 9, 0

0, 13, 11, 0

QLQX + CAM

CAM

24

â‘¡â‘¢

Fu et al. 2016 [30]

30/30

22/8

23/7

56.6 ± 18.8

58.4 ± 19.3

0, 12, 18, 0

0, 10, 20, 0

QLQX + CAM

CAM

4

â‘ â‘¡â‘¢

Ma et al. 2016 [31]

31/32

34/29

–

–

QLQX + CAM

CAM

24

â‘ â‘¡

Wu et al. 2016 [32]

30/30

19/11

20/10

56.7 ± 7.8

57.3 ± 7.1

0, 5, 13, 12

0, 6, 14, 10

QLQX + CAM

CAM

12

②④⑤

Leng, 2016 [33]

31/31

21/10

16/15

54.65 ± 9.33

55.19 ± 7.55

0, 0, 12, 19

0, 0, 13, 18

QLQX + CAM

CAM

4

②③④⑤

Jing et al. 2017 [34]

43/42

21/22

19/23

41.3 ± 10.1

41.1 ± 9.8

–

QLQX + CAM

CAM

2

①②③④⑤

Wu et al. 2018 [35]

278/278

139/139

158/120

49.94 ± 21.58

53.19 ± 19.57

0, 165, 113, 0

0, 184, 94, 0

QLQX + CAM

CAM

48

â‘¡â‘¢

Zhao, 2018 [36]

40/40

24/16

26/14

61.5 ± 12.3

62.2 ± 12.6

0, 13, 18, 9

0, 12, 18, 10

QLQX + CAM

CAM

4

②③④⑤

Yao, 2018 [37]

48/48

30/18

29/19

54.60 ± 5.61

55.21 ± 4.68

–

QLQX + CAM

CAM

4

â‘ 

Huang, 2018 [38]

30/30

19/11

18/12

52.1 ± 3.2

52.2 ± 3.4

0, 0, 21, 9

0, 0, 20, 10

QLQX + CAM

CAM

4

â‘ â‘¡

Wang et al. 2019 [39]

68/68

35/33

38/30

67.98 ± 6.03

68.54 ± 6.12

0, 24, 44, 0

0, 26, 42, 0

QLQX + CAM

CAM

4

①②⑤

Ren et al. 2019 [40]

64/64

34/30

32/32

71.4 ± 6.2

70.3 ± 5.8

–

QLQX + CAM

CAM

2

â‘ â‘¡â‘¢

Liu et al. 2019 [41]

41/41

18/23

19/22

41.41 ± 5.35

41.39 ± 5.32

–

QLQX + CAM

CAM

2

①②③⑤

Zheng et al. 2019 [42]

52/52

29/23

28/24

42.14 ± 7.62

41.95 ± 7.84

0, 7, 29, 16

0, 5, 30, 17

QLQX + CAM

CAM

2

â‘ â‘¡â‘¢

Dong, 2019 [43]

40/39

26/14

25/14

53.7 ± 10.6

54.9 ± 11.2

0, 14, 18, 8

0, 13, 19, 7

QLQX + CAM

CAM

2

①②③④

Yang et al. 2019 [44]

60/58

35/25

33/25

49.14 ± 13.52

47.89 ± 12.83

0, 23, 22, 15

0, 21, 24, 13

QLQX + CAM

CAM

24

â‘¡â‘¢

Dai et al. 2019 [45]

48/47

25/23

25/22

37.72 ± 3.85

37.86 ± 3.71

0, 0, 24, 24

0, 0, 23, 24

QLQX + CAM

CAM

12

â‘ â‘¡

Shi, 2020 [46]

30/30

16/14

17/13

65.5 ± 3.4

65.4 ± 3.6

0, 10, 20, 0

0, 11, 19, 0

QLQX + CAM

CAM

4

â‘ â‘¡

Li et al. 2020 [47]

40/40

27/13

26/14

54.58 ± 9.23

54.74 ± 9.36

0, 11, 19, 10

0, 12, 17, 11

QLQX + CAM

CAM

4

â‘¡â‘¢

Niu et al. 2020 [48]

68/67

42/26

41/26

47.05 ± 5.01

46.75 ± 5.012

0, 29, 24, 15

0, 30, 23, 14

QLQX + CAM

CAM

4

â‘ â‘¡â‘£

Yao et al. 2020 [49]

48/48

25/23

28/20

50.43 ± 6.24

50.53 ± 6.12

0, 24, 18, 6

0, 27, 16, 5

QLQX + CAM

CAM

12

①②③⑥

Li, 2020 [50]

30/30

21/9

22/8

65.78 ± 2.21

65.89 ± 2.46

–

QLQX + CAM

CAM

2

â‘ 

Meng, 2020 [51]

50/50

27/23

26/24

58.19 ± 3.25

58.25 ± 3.67

–

QLQX + CAM

CAM

2

①②③④⑤

Wang et al. 2020 [52]

40/40

26/14

24/16

68.63 ± 4.57

68.77 ± 7.16

0, 14, 18, 8

0, 13, 18, 9

QLQX + CAM

CAM

4

â‘ â‘¡â‘¢

Wang et al. 2020 [53]

45/41

30/15

27/14

54.4 ± 10.8

53.9 ± 11.3

0, 9, 29, 7

0, 8, 28, 5

QLQX + CAM

CAM

8

①②③④

Dong, 2021 [54]

30/30

24/6

22/8

53.53 ± 10.03

52.27 ± 8.76

–

QLQX + CAM

CAM

12

①②③④

Li, 2021 [55]

50/50

27/23

26/24

65.12 ± 4.18

64.78 ± 4.68

0, 15, 22, 13

0, 16, 20, 14

QLQX + CAM

CAM

24

①②③④⑤

Zhang, 2022 [56]

40/40

–

–

–

QLQX + CAM

CAM

12

①②③④

Tan et al. 2022 [57]

42/41

22/20

21/20

68.42 ± 10.30

67.56 ± 6.83

–

QLQX + CAM

CAM

12

â‘ â‘¡â‘¢

Wang et al. 2022 [58]

40/40

28/12

27/13

58.23 ± 11.22

59.90 ± 12.03

0, 19, 15, 6

0, 19, 16, 5

QLQX + CAM

CAM

12

①②③④

Wu et al. 2022 [59]

46/46

25/21

26/20

39.41 ± 6.37

38.56 ± 6.26

0, 16, 27, 3

0, 17, 25, 4

QLQX + CAM

CAM

12

â‘ â‘¡â‘¢

Pan, 2022 [60]

43/43

22/21

23/20

59.78 ± 2.32

59.89 ± 2.24

0, 19, 17, 7

0, 18, 16, 9

QLQX + CAM

CAM

12

â‘ â‘¡â‘¥

Yan et al. 2023 [61]

30/30

17/13

18/12

–

–

QLQX + CAM

CAM

12

①②③⑤

Han et al. 2023 [62]

39/39

18/21

16/23

43.33 ± 3.92

43.26 ± 3.85

0, 15, 12, 12

0, 16, 14, 9

QLQX + CAM

CAM

4

①②③④

Zhang et al. 2023 [63]

60/60

31/29

32/28

74.51 ± 4.67

74.74 ± 4.81

0, 27, 21, 12

0, 25, 22, 13

QLQX + CAM

CAM

16

â‘ â‘¡â‘¥

Liu, 2023 [64]

44/44

30/14

32/12

64.78 ± 8.46

65.32 ± 8.25

0, 18, 17, 9

0, 15, 20, 9

QLQX + CAM

CAM

12

â‘¡

Luo et al. 2006 [65]

40/46

–

–

–

WX + CAM

CAM

2

â‘ 

Cui et al. 2009 [66]

28/32

35/25

48 ± 6

–

WX + CAM

CAM

12

â‘¡â‘£

Zhao et al. 2009 [67]

84/84

43/41

40/44

–

–

WX + CAM

CAM

4

â‘ 

Wu et al. 2010 [68]

22/23

28/17

35 ± 5.5

–

WX + CAM

CAM

12

â‘¡â‘£

Liu, 2012 [69]

50/50

25/25

24/26

–

–

WX + CAM

CAM

2

â‘ 

Feng, 2013 [70]

32/32

20/12

21/11

49.6 ± 5.3

50.4 ± 5.9

0, 7, 25, 0

0, 7, 25, 0

WX + CAM

CAM

4

â‘ â‘¡

Wang, 2014 [71]

28/28

16/12

18/10

52.4 ± 4.31

–

WX + CAM

CAM

4

â‘ 

Wang, 2017 [72]

50/50

27/23

24/26

45.5 ± 5.7

44.8 ± 4.9

–

WX + CAM

CAM

4

â‘ 

Li et al. 2019 [73]

23/23

14/9

7/16

50.17 ± 10.20

50.83 ± 10.18

0, 0, 15, 8

0, 0, 16, 7

WX + CAM

CAM

12

â‘ â‘¡â‘£

He et al. 2019 [74]

30/30

21/9

20/10

52.97 ± 6.98

52.81 ± 6.27

0, 5, 11, 14

0, 5, 10, 15

WX + CAM

CAM

12

â‘ â‘¡â‘¢

Tan et al. 2021 [75]

68/68

37/31

35/33

60.7 ± 0.2

60.6 ± 0.3

0, 7, 21, 40

0, 8, 21, 39

WX + CAM

CAM

12

①②③④

Ding, 2006 [76]

89/30

48/41

18/12

–

0, 4, 48, 37

0, 2, 16, 12

TXL + CAM

CAM

24

â‘ â‘¡

Chen et al. 2019 [77]

43/43

20/23

22/21

65.1 ± 10.3

68.5 ± 9.2

0, 15, 19, 9

0, 13, 20, 10

TXL + CAM

CAM

8

①②④⑤⑥

Li et al. 2019 [78]

44/44

25/19

23/21

52.1 ± 6.5

51.2 ± 6.1

17, 17, 10, 0

14, 21, 9, 0

TXL + CAM

CAM

8

①②③⑤⑥

Liang et al. 2020 [79]

73/73

43/30

46/27

53.3 ± 5.7

53.3 ± 5.7

35, 27, 11, 0

36, 27, 10, 0

TXL + CAM

CAM

8

â‘ â‘¡â‘¢

Li et al. 2020 [80]

56/56

36/20

35/21

62.73 ± 14.15

61.96 ± 13.88

0, 21, 23, 12

0, 20, 25, 11

TXL + CAM

CAM

12

①②③⑤

Cao, 2020 [81]

42/42

19/23

20/22

47.08 ± 3.53

46.92 ± 3.33

0, 16, 20, 6

0, 17, 20, 5

TXL + CAM

CAM

8

②③⑤⑥

Zhou et al. 2021 [82]

48/48

25/23

27/21

46.70 ± 6.19

45.90 ± 5.93

17, 19, 12, 0

18, 20, 10, 0

TXL + CAM

CAM

1

â‘ â‘¡

Zhu, 2021 [83]

42/42

24/18

25/17

54.52 ± 4.78

55.02 ± 4.93

–

TXL + CAM

CAM

12

â‘ â‘¡â‘¢

He et al. 2011 [84]

28/25

20/8

15/10

60 ± 18

58 ± 16

–

QSYQ + CAM

CAM

48

â‘ â‘¡â‘¢

Wang et al. 2013 [85]

60/60

72/48

67.5 ± 5.5

–

QSYQ + CAM

CAM

6

â‘ 

Wang, 2007 [86]

30/20

18/12

12/8

41 ± 15

39.5 ± 13.5

0, 12, 13, 5

0, 8, 10, 2

SXBX + CAM

CAM

4

â‘ â‘¢

Deng et al. 2013 [87]

65/67

76/56

62 ± 11

–

SXBX + CAM

CAM

12

②⑤

Ma et al. 2018 [88]

30/30

17/13

17/13

35.41 ± 13.02

34.51 ± 10.32

0, 16, 14, 0

0, 14, 16, 0

SXBX + CAM

CAM

8

①②④⑥

Qian et al. 2012 [89]

56/56

64/48

63 ± 17

  

YXST + CAM

CAM

12

â‘ â‘¡â‘¢

Fu et al. 2014 [90]

64/62

42/22

40/22

65 ± 10.2

64 ± 10.8

0, 0, 48, 16

0, 0, 46, 16

YXST + CAM

CAM

12

â‘ â‘¡

Wang et al. 2013 [91]

60/60

37/23

38/22

52.34 ± 9.18

51.52 ± 10.20

–

YXSC + CAM

CAM

12

â‘ â‘¡â‘£

Jiang, 2013 [92]

30/30

21/9

20/10

40 ± 12

41 ± 11

0, 14, 13, 3

0, 15, 12, 3

YXSC + CAM

CAM

12

①②③④

Cen et al. 2020 [93]

45/45

24/21

23/22

54.9 ± 10.2

53.9 ± 10.2

0, 0, 26, 19

0, 0, 25, 20

GTTL + CAM

CAM

8

①②③⑥

Wang, 2022 [94]

35/35

20/15

19/16

56.99 ± 5.33

57.69 ± 5.32

0, 17, 18, 0

0, 19, 16, 0

GTTL + CAM

CAM

24

â‘ â‘¡â‘¢

  1. Age is expressed as mean ± standard deviation
  2. ① clinical effectiveness rate (CER), ② left ventricular ejection fraction (LVEF), ③ left ventricular end-diastolic dimension (LVEDD), ④ six-min walk test (6MWT), ⑤ brain natriuretic peptide (BNP), and ⑥ cardiac output (CO)
  3. E experimental group, C control group, QLQX Qili Qiangxin capsule, WX Wenxin granule, TXL Tongxinluo capsule, QSYQ Qishen Yiqi dropping pill, SXBX Shexiang Baoxin pill, YXST Yangxinshi tablet, YXSC Yixinshu capsule, GTTL Getong Tongluo capsule, CAM complementary and alternative medicine